skip to Main Content

Biosimilars

Fulfilling the promise of biosimilars has proven more elusive than initially expected. Learn how healthcare stakeholders are evaluating a biosimilars market.

Commercial Uncertainty Remains as U.S. Biosimilar Pipeline Matures

With the recent announcement of the U.S. Food and Drug Administration's (FDA) acceptance of a submission for approval of a second biosimilar to Remicade (infliximab), questions remain for biologics manufacturers, payers, prescribers, and others as to how a mature biosimilars pipeline will begin to evolve in the United States and whether a sustainable competitive specialty market will develop.

Back To Top